Establishment Labs (NASDAQ:ESTA) Stock Price Down 3.7% – Should You Sell?

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) traded down 3.7% during mid-day trading on Thursday . The company traded as low as $72.70 and last traded at $71.9450. 95,954 shares were traded during trading, a decline of 81% from the average session volume of 496,393 shares. The stock had previously closed at $74.71.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ESTA shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Monday. Canaccord Genuity Group boosted their price target on Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a report on Wednesday. Needham & Company LLC lifted their price objective on Establishment Labs from $70.00 to $84.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Finally, Wall Street Zen upgraded Establishment Labs from a “sell” rating to a “hold” rating in a research note on Sunday, October 19th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $78.14.

Establishment Labs Stock Down 7.4%

The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -24.36 and a beta of 1.01. The business has a fifty day simple moving average of $60.41 and a two-hundred day simple moving average of $47.30. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Wednesday, November 5th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.16. Establishment Labs had a negative return on equity of 235.45% and a negative net margin of 43.45%.The business had revenue of $53.78 million during the quarter, compared to the consensus estimate of $52.28 million. During the same quarter last year, the company earned ($0.59) EPS. Establishment Labs’s revenue was up 33.8% on a year-over-year basis. Equities analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Institutional Investors Weigh In On Establishment Labs

A number of hedge funds have recently made changes to their positions in ESTA. NewEdge Advisors LLC increased its holdings in shares of Establishment Labs by 3,702.4% during the third quarter. NewEdge Advisors LLC now owns 9,468 shares of the company’s stock worth $388,000 after buying an additional 9,219 shares in the last quarter. PharVision Advisers LLC bought a new stake in Establishment Labs during the 3rd quarter worth approximately $203,000. Voleon Capital Management LP acquired a new stake in Establishment Labs during the 3rd quarter valued at $1,287,000. Vestal Point Capital LP bought a new position in Establishment Labs in the 3rd quarter valued at $4,099,000. Finally, Strategic Wealth Partners Ltd. raised its position in Establishment Labs by 63.7% in the 3rd quarter. Strategic Wealth Partners Ltd. now owns 71,807 shares of the company’s stock valued at $2,943,000 after purchasing an additional 27,931 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.